Neil  Stahl net worth and biography

Neil Stahl Biography and Net Worth

Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.

What is Neil Stahl's net worth?

The estimated net worth of Neil Stahl is at least $51.01 million as of August 22nd, 2023. Mr. Stahl owns 53,100 shares of Regeneron Pharmaceuticals stock worth more than $51,008,391 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Stahl may own. Learn More about Neil Stahl's net worth.

How do I contact Neil Stahl?

The corporate mailing address for Mr. Stahl and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Neil Stahl's contact information.

Has Neil Stahl been buying or selling shares of Regeneron Pharmaceuticals?

Neil Stahl has not been actively trading shares of Regeneron Pharmaceuticals within the last three months. Most recently, Neil Stahl sold 11,665 shares of the business's stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $840.98, for a transaction totalling $9,810,031.70. Following the completion of the sale, the executive vice president now directly owns 53,100 shares of the company's stock, valued at $44,656,038. Learn More on Neil Stahl's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 32 times. They sold a total of 60,285 shares worth more than $52,060,139.46. The most recent insider tranaction occured on March, 14th when EVP Andrew J Murphy sold 5,783 shares worth more than $5,531,266.01. Insiders at Regeneron Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 3/14/2024.

Neil Stahl Insider Trading History at Regeneron Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2023Sell11,665$840.98$9,810,031.7053,100View SEC Filing Icon  
8/5/2022Sell23,782$612.61$14,569,091.0252,795View SEC Filing Icon  
4/14/2020Sell5,497$521.07$2,864,321.7924,459View SEC Filing Icon  
2/27/2020Sell10,349$452.26$4,680,438.7436,380View SEC Filing Icon  
11/26/2019Sell4,006$364.07$1,458,464.4232,455View SEC Filing Icon  
11/8/2019Sell7,364$338.52$2,492,861.2821,150View SEC Filing Icon  
5/14/2019Sell9,853$305.74$3,012,456.2247,450View SEC Filing Icon  
5/24/2018Sell11,407$295.09$3,366,091.6358,709View SEC Filing Icon  
6/22/2017Sell8,306$532.55$4,423,360.3043,950View SEC Filing Icon  
6/15/2017Sell8,567$468.45$4,013,211.1544,245View SEC Filing Icon  
6/2/2017Sell2,812$479.49$1,348,325.8828,477View SEC Filing Icon  
11/9/2015Sell42,101$561.45$23,637,606.4522,029View SEC Filing Icon  
11/24/2014Sell5,307$412.93$2,191,419.51View SEC Filing Icon  
8/11/2014Sell11,646$339.96$3,959,174.16View SEC Filing Icon  
8/8/2014Sell2,841$340.60$967,644.60View SEC Filing Icon  
2/13/2014Sell22,612$318.82$7,209,157.8424,391View SEC Filing Icon  
5/13/2013Sell23,038$276.88$6,378,761.44View SEC Filing Icon  
See Full Table

Neil Stahl Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Neil Stahl's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $962.49
Low: $959.25
High: $970.79

50 Day Range

MA: $957.54
Low: $929.13
High: $993.35

2 Week Range

Now: $962.49
Low: $684.80
High: $998.33

Volume

447,306 shs

Average Volume

501,967 shs

Market Capitalization

$105.64 billion

P/E Ratio

27.70

Dividend Yield

N/A

Beta

0.11